symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ARMP,2.13,0.613095,177839,76951149,0,0.83-5.26,0.06,"Armata Pharmaceuticals, Inc.",USD,0000921114,US04216R1023,04216R102,American Stock Exchange,AMEX,Biotechnology,https://www.armatapharma.com,"Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.",Dr. Deborah L. Birx M.D.,Healthcare,US,72,858 829 0829,4503 Glencoe Avenue,Marina del Rey,CA,90292,0.563186,2.72681,https://financialmodelingprep.com/image-stock/ARMP.png,1994-05-20,False,False,True,False,False
